Matthew Henn

Company: Seres Therapeutics

Job title: Executive Vice Pesident & Chief Scientific Officer

Seminars:

Breakthrough in GI-Derived Bloodstream Infection Reduction: SER-155’s FDA Designation 9:30 am

Highlighting the significant reduction in bacterial bloodstream infections demonstrated in Phase 1b trials of SER-155 and its impact on patient outcomes Discussing the significance of FDA breakthrough therapy designation and fast track status for expedited development and regulatory collaboration Exploring the future development plans for SER-155, including its potential applications in various high-risk patient populationsRead more

day: Conference Day Two, 7:30 - 10:00